Trevi Therapeutics, Inc.
TRVI
$6.47
$0.121.89%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 13.80% | -7.21% | -13.30% | -39.39% | -1.60% |
| Total Depreciation and Amortization | 5.56% | -5.26% | 8.57% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 64.59% | -45.02% | 95.67% | 53.49% | 70.06% |
| Change in Net Operating Assets | -68.00% | 15.62% | 4,498.39% | -108.42% | 255.56% |
| Cash from Operations | 0.06% | -10.05% | 17.04% | -64.60% | 12.64% |
| Capital Expenditure | -- | 100.00% | -- | -- | -22.22% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -411.27% | 174.21% | 134.56% | -162.88% | -28.52% |
| Cash from Investing | -411.36% | 176.99% | 134.21% | -162.99% | -28.57% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 3.13% | -3.23% | 3.13% | 0.00% | -3.23% |
| Issuance of Common Stock | 927.90% | -1.73% | 127,350.00% | -88.89% | -97.90% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 66.28% |
| Cash from Financing | 933.89% | -1.76% | 18,196.43% | 48.15% | -103.58% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 484.17% | 464.27% | 95.44% | -388.96% | -47.33% |